Prognosis
Scientists Defend Trial Questioning Remdesivir’s Covid Benefits
- WHO study data have ‘not undergone rigorous review’: Gilead
- Earlier U.S. trial had shown drug reduced recovery times
Photographer: Ulrich Perrey/AFP via Getty Images
This article is for subscribers only.
Sign up here for our daily coronavirus newsletter on what you need to know, and subscribe to our Covid-19 podcast for the latest news and analysis.
Scientists defended a World Health Organization trial showing that the antiviral treatment remdesivir doesn’t save the lives of Covid-19 patients after drugmaker Gilead Sciences Inc. criticized the findings.